Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Erhart F, Buchroithner J, Reitermaier R, Fischhuber K, Klingenbrunner S, Sloma I, Hibsh D, Kozol R, Efroni S, Ricken G, Wöhrer A, Haberler C, Hainfellner J, Krumpl G, Felzmann T, Dohnal AM, Marosi C, Visus C.

Acta Neuropathol Commun. 2018 Dec 5;6(1):135. doi: 10.1186/s40478-018-0621-2.

2.

Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma.

Handisurya A, Rumpold T, Caucig-Lütgendorf C, Flechl B, Preusser M, Ilhan-Mutlu A, Dieckmann K, Widhalm G, Grisold A, Wöhrer A, Hainfellner J, Ristl R, Kurz C, Marosi C, Gessl A, Hassler M.

Radiother Oncol. 2018 Oct 30. pii: S0167-8140(18)33538-2. doi: 10.1016/j.radonc.2018.10.014. [Epub ahead of print]

PMID:
30389240
3.

Cancer rehabilitation: current trends and practices within an Austrian University Hospital Center†.

Crevenna R, Kainberger F, Wiltschke C, Marosi C, Wolzt M, Cenik F, Keilani M.

Disabil Rehabil. 2018 Oct 17:1-6. doi: 10.1080/09638288.2018.1514665. [Epub ahead of print]

PMID:
30328719
4.

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.

Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, Nowosielski M, Iglseder S, Freyschlag CF, Oberndorfer S, Bordihn K, von Campe G, Hoffermann M, Ruckser R, Rössler K, Spiegl-Kreinecker S, Fischer MB, Czech T, Visus C, Krumpl G, Felzmann T, Marosi C.

Cancers (Basel). 2018 Oct 5;10(10). pii: E372. doi: 10.3390/cancers10100372.

5.

Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer.

Grilz E, Posch F, Königsbrügge O, Schwarzinger I, Lang IM, Marosi C, Pabinger I, Ay C.

Thromb Haemost. 2018 Nov;118(11):1875-1884. doi: 10.1055/s-0038-1673401. Epub 2018 Oct 8.

PMID:
30296815
6.

The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space.

Klughammer J, Kiesel B, Roetzer T, Fortelny N, Nemc A, Nenning KH, Furtner J, Sheffield NC, Datlinger P, Peter N, Nowosielski M, Augustin M, Mischkulnig M, Ströbel T, Alpar D, Ergüner B, Senekowitsch M, Moser P, Freyschlag CF, Kerschbaumer J, Thomé C, Grams AE, Stockhammer G, Kitzwoegerer M, Oberndorfer S, Marhold F, Weis S, Trenkler J, Buchroithner J, Pichler J, Haybaeck J, Krassnig S, Mahdy Ali K, von Campe G, Payer F, Sherif C, Preiser J, Hauser T, Winkler PA, Kleindienst W, Würtz F, Brandner-Kokalj T, Stultschnig M, Schweiger S, Dieckmann K, Preusser M, Langs G, Baumann B, Knosp E, Widhalm G, Marosi C, Hainfellner JA, Woehrer A, Bock C.

Nat Med. 2018 Oct;24(10):1611-1624. doi: 10.1038/s41591-018-0156-x. Epub 2018 Aug 27.

PMID:
30150718
7.

The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma.

Rainer E, Wang H, Traub-Weidinger T, Widhalm G, Fueger B, Chang J, Zhu Z, Marosi C, Haug A, Hacker M, Li S.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2396-2403. doi: 10.1007/s00259-018-4088-y. Epub 2018 Jul 30.

8.

How should adult patients with neurofibromatosis 1 be managed?

Nöbauer-Huhmann IM, Brodowicz T, Marosi C.

Neuro Oncol. 2018 May 18;20(6):721-722. doi: 10.1093/neuonc/noy050. No abstract available.

PMID:
29788480
9.

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.

Mir Seyed Nazari P, Riedl J, Preusser M, Posch F, Thaler J, Marosi C, Birner P, Ricken G, Hainfellner JA, Pabinger I, Ay C.

J Thromb Haemost. 2018 Jun;16(6):1121-1127. doi: 10.1111/jth.14129. Epub 2018 May 20.

10.

Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?

Marosi C.

EBioMedicine. 2018 Mar;29:9-10. doi: 10.1016/j.ebiom.2018.02.018. Epub 2018 Feb 21. No abstract available.

11.

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.

Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24.

12.

Impaired mixed emotion processing in the right ventrolateral prefrontal cortex in schizophrenia: an fMRI study.

Szabó ÁG, Farkas K, Marosi C, Kozák LR, Rudas G, Réthelyi J, Csukly G.

BMC Psychiatry. 2017 Dec 8;17(1):391. doi: 10.1186/s12888-017-1558-x.

13.

Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients.

Pavo N, Raderer M, Goliasch G, Wurm R, Strunk G, Cho A, Novak JF, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider ST, Parschalk B, Scheithauer W, Pirker R, Kiesewetter B, Pacher R, Zielinski C, Hülsmann M.

Oncotarget. 2017 Apr 16;8(46):81250-81260. doi: 10.18632/oncotarget.17131. eCollection 2017 Oct 6.

14.

Brain tumors - other treatment modalities.

Peyrl A, Frischer J, Hainfellner JA, Preusser M, Dieckmann K, Marosi C.

Handb Clin Neurol. 2017;145:547-560. doi: 10.1016/B978-0-12-802395-2.00034-1. Review.

PMID:
28987193
15.

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.

Micko ASG, Wöhrer A, Höftberger R, Vila G, Marosi C, Knosp E, Wolfsberger S.

Pituitary. 2017 Dec;20(6):643-653. doi: 10.1007/s11102-017-0829-3.

16.

Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment.

Schneider M, Reitter EM, Kastner MT, Thannesberger J, Rieder FJJ, Preusser M, Marosi C, Steininger C.

Neuro Oncol. 2017 Sep 1;19(9):1280-1282. doi: 10.1093/neuonc/nox065. No abstract available.

17.

The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma.

Flechl B, Sax C, Ackerl M, Crevenna R, Woehrer A, Hainfellner J, Preusser M, Widhalm G, Kiesel B, Lütgendorf-Caucig C, Dieckmann K, Steffal C, Marosi C, Hassler MR.

Radiother Oncol. 2017 Nov;125(2):228-233. doi: 10.1016/j.radonc.2017.07.027. Epub 2017 Aug 8.

PMID:
28801008
18.

The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.

Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC.

ESMO Open. 2017 Jul 16;2(3):e000166. doi: 10.1136/esmoopen-2017-000166. eCollection 2017.

19.

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Aug;18(8):e430-e431. doi: 10.1016/S1470-2045(17)30515-6. Epub 2017 Jul 26. No abstract available.

20.

European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma.

Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R, Marosi C, Le Rhun E, Grant R, Oliver K, Oberg I, Bulbeck HJ, Rooney AG, Henriksson R, Pasman HRW, Oberndorfer S, Weller M, Taphoorn MJB; European Association of Neuro-Oncology palliative care task force.

Lancet Oncol. 2017 Jun;18(6):e330-e340. doi: 10.1016/S1470-2045(17)30345-5. Review.

21.

Correlation of immune phenotype with IDH mutation in diffuse glioma.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M.

Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054.

22.

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5. Review. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

23.

Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).

Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, Brada M, Carapella CM, Preusser M, Le Rhun E, Rudà R, Tonn JC, Weber DC, Weller M.

Neuro Oncol. 2017 Feb 1;19(2):162-174. doi: 10.1093/neuonc/now241.

24.

Milestones of the last 10 years: CNS cancer.

Marosi C, Preusser M.

Memo. 2017;10(1):18-21. doi: 10.1007/s12254-016-0309-x. Epub 2017 Jan 25. Review.

25.

Neuro-oncology in 2016: Advances in brain tumour classification and therapy.

Preusser M, Marosi C.

Nat Rev Neurol. 2017 Feb;13(2):71-72. doi: 10.1038/nrneurol.2017.3. Epub 2017 Jan 20. No abstract available.

PMID:
28106065
26.

Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.

Riedl J, Preusser M, Nazari PM, Posch F, Panzer S, Marosi C, Birner P, Thaler J, Brostjan C, Lötsch D, Berger W, Hainfellner JA, Pabinger I, Ay C.

Blood. 2017 Mar 30;129(13):1831-1839. doi: 10.1182/blood-2016-06-720714. Epub 2017 Jan 10.

27.

Challenge of cancer in the elderly.

Marosi C, Köller M.

ESMO Open. 2016 Apr 12;1(3):e000020. eCollection 2016. Review.

28.

Gamma Knife Radiosurgery in Recurrent Glioblastoma.

Frischer JM, Marosi C, Woehrer A, Hainfellner JA, Dieckmann KU, Eiter H, Wang WT, Mallouhi A, Ertl A, Knosp E, Filipits M, Kitz K, Gatterbauer B.

Stereotact Funct Neurosurg. 2016;94(4):265-272. Epub 2016 Oct 8.

PMID:
27721311
29.

Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.

Riedl J, Kaider A, Marosi C, Prager GW, Eichelberger B, Assinger A, Pabinger I, Panzer S, Ay C.

Thromb Haemost. 2017 Jan 5;117(1):90-98. doi: 10.1160/TH16-02-0123. Epub 2016 Oct 20.

PMID:
27761580
30.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJ, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

31.

Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status.

Grabner G, Kiesel B, Wöhrer A, Millesi M, Wurzer A, Göd S, Mallouhi A, Knosp E, Marosi C, Trattnig S, Wolfsberger S, Preusser M, Widhalm G.

Eur Radiol. 2017 Apr;27(4):1556-1567. doi: 10.1007/s00330-016-4451-y. Epub 2016 Jun 14.

32.

PO-63 - Exhausted platelets in cancer patients with high risk of venous thromboembolism and poor prognosis.

Riedl J, Kaider A, Marosi C, Prager G, Eichelberger B, Koder S, Panzer S, Pabinger I, Ay C.

Thromb Res. 2016 Apr;140 Suppl 1:S199-200. doi: 10.1016/S0049-3848(16)30196-7. Epub 2016 Apr 8.

PMID:
27161749
33.

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME.

Clin Cancer Res. 2016 Oct 1;22(19):4797-4806. Epub 2016 May 3.

34.

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG.

Neuro Oncol. 2016 Apr;18(4):549-56. doi: 10.1093/neuonc/nov326. Epub 2016 Jan 27.

35.

Deficits in low beta desynchronization reflect impaired emotional processing in schizophrenia.

Csukly G, Farkas K, Marosi C, Szabó Á.

Schizophr Res. 2016 Mar;171(1-3):207-14. doi: 10.1016/j.schres.2016.01.031. Epub 2016 Jan 23.

PMID:
26817399
36.

Cancer rehabilitation in Austria--aspects of Physical Medicine and Rehabilitation.

Maehr B, Keilani M, Wiltschke C, Hassler M, Licht T, Marosi C, Huetterer E, Cenik F, Crevenna R.

Wien Med Wochenschr. 2016 Feb;166(1-2):39-43. doi: 10.1007/s10354-015-0414-1. Epub 2016 Jan 12. Review.

PMID:
26758980
37.

Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.

Reitter EM, Kaider A, Ay C, Quehenberger P, Marosi C, Zielinski C, Pabinger I.

J Thromb Haemost. 2016 Feb;14(2):294-305. doi: 10.1111/jth.13218. Epub 2016 Jan 29.

38.

The PERS(2) ON score for systemic assessment of symptomatology in palliative care: a pilot study.

Masel EK, Berghoff AS, Schur S, Maehr B, Schrank B, Simanek R, Preusser M, Marosi C, Watzke HH.

Eur J Cancer Care (Engl). 2016 Jul;25(4):544-50. doi: 10.1111/ecc.12419. Epub 2015 Nov 12.

PMID:
26564404
39.

Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.

Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R.

Heart. 2015 Dec;101(23):1874-80. doi: 10.1136/heartjnl-2015-307848. Epub 2015 Sep 28.

PMID:
26416836
40.

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.

Furtner J, Schöpf V, Seystahl K, Le Rhun E, Rudà R, Roelcke U, Koeppen S, Berghoff AS, Marosi C, Clement P, Faedi M, Watts C, Wick W, Soffietti R, Weller M, Preusser M.

Neuro Oncol. 2016 Mar;18(3):401-7. doi: 10.1093/neuonc/nov183. Epub 2015 Sep 9.

41.

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions.

Bienkowski M, Berghoff AS, Marosi C, Wöhrer A, Heinzl H, Hainfellner JA, Preusser M.

Clin Neuropathol. 2015 Sep-Oct;34(5):250-7. Review.

42.

Elementary sensory deficits in schizophrenia indexed by impaired visual mismatch negativity.

Farkas K, Stefanics G, Marosi C, Csukly G.

Schizophr Res. 2015 Aug;166(1-3):164-70. doi: 10.1016/j.schres.2015.05.011. Epub 2015 Jun 11.

PMID:
26072712
43.

Influence of adjunctive classical homeopathy on global health status and subjective wellbeing in cancer patients - A pragmatic randomized controlled trial.

Frass M, Friehs H, Thallinger C, Sohal NK, Marosi C, Muchitsch I, Gaertner K, Gleiss A, Schuster E, Oberbaum M.

Complement Ther Med. 2015 Jun;23(3):309-17. doi: 10.1016/j.ctim.2015.03.004. Epub 2015 Mar 23.

PMID:
26051564
44.

Antiangiogenic treatment of meningiomas.

Preusser M, Marosi C.

Curr Treat Options Neurol. 2015 Jul;17(7):359. doi: 10.1007/s11940-015-0359-0.

PMID:
25975819
45.

Association of platelet activation markers with cancer-associated venous thromboembolism.

Riedl J, Hell L, Kaider A, Koder S, Marosi C, Zielinski C, Panzer S, Pabinger I, Ay C.

Platelets. 2016;27(1):80-5. doi: 10.3109/09537104.2015.1041901. Epub 2015 May 13.

PMID:
25970326
46.

Monitoring the early signs of cognitive decline in elderly by computer games: an MRI study.

Sirály E, Szabó Á, Szita B, Kovács V, Fodor Z, Marosi C, Salacz P, Hidasi Z, Maros V, Hanák P, Csibri É, Csukly G.

PLoS One. 2015 Feb 23;10(2):e0117918. doi: 10.1371/journal.pone.0117918. eCollection 2015.

47.

Response to imatinib as a function of target kinase expression in recurrent glioblastoma.

Hassler MR, Vedadinejad M, Flechl B, Haberler C, Preusser M, Hainfellner JA, Wöhrer A, Dieckmann KU, Rössler K, Kast R, Marosi C.

Springerplus. 2014 Feb 25;3:111. doi: 10.1186/2193-1801-3-111. eCollection 2014.

48.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.

Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

49.

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.

Kurscheid S, Bady P, Sciuscio D, Samarzija I, Shay T, Vassallo I, Criekinge WV, Daniel RT, van den Bent MJ, Marosi C, Weller M, Mason WP, Domany E, Stupp R, Delorenzi M, Hegi ME.

Genome Biol. 2015 Jan 27;16:16. doi: 10.1186/s13059-015-0583-7.

50.

Assessing MGMT methylation status and its current impact on treatment in glioblastoma.

Berghoff AS, Hainfellner JA, Marosi C, Preusser M.

CNS Oncol. 2015;4(1):47-52. doi: 10.2217/cns.14.50. Review.

Supplemental Content

Loading ...
Support Center